Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next.

Alpha Tau Medical (DRTS) shares rose after Piper Sandler upgraded the stock to Overweight, citing expected catalysts over the next year. Analyst Allison Bratzel highlighted the company's potential in oncology therapeutics.

Piper Sandler upgraded Alpha Tau Medical to Overweight from Neutral and raised its price target to $22 from $8, a 175% increase. This implies a 99.5% downside from the Nov 11 close of $4515.

Alpha Tau Medical (NASDAQ: DRTS) received FDA approval to expand its U.S. brain cancer trial, doubling enrollment to 20 patients. The company will present updated REGAIN trial data on November 13, including new measures like progression-free survival and quality of life. Alpha DaRT technology aims to treat recurrent glioblastoma with localized radiation.

Alpha Tau Medical (NASDAQ:DRTS) received FDA approval to expand its REGAIN trial for recurrent glioblastoma, increasing enrollment to 20 patients and adding new endpoints. The trial, presented at the Society for Neuro-Oncology Annual Meeting, evaluates the safety and feasibility of Alpha DaRT therapy. Alpha Tau's treatment is not yet approved for commercial use.

Alpha Tau Medical Ltd. (DRTS) received FDA approval to expand its REGAIN trial for recurrent glioblastoma from 10 to 20 patients, adding secondary endpoints and an interim analysis. The company plans to present new data at SNO 2026.

Alpha Tau Medical Ltd. (DRTS) announced FDA approval to expand its REGAIN trial for recurrent glioblastoma to 20 patients, adding new endpoints. The company will present trial data at the 2026 Society for Neuro-Oncology Annual Meeting, marking the trial's first scientific presentation. The expanded study includes progression-free survival and quality-of-life assessments.